相关实验视频

Updated: Jan 15, 2026

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

主要与年龄相关的病症

Timothy E Richardson^1,2, Jamie M Walker^3,4,5,6,7, Kurt Farrell^3,4,6,8

¹Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, Icahn Building, 9.20E, 1468 Madison Avenue, New York, NY, 10029, USA. timothy.richardson@mountsinai.org.

Acta neuropathologica

|October 9, 2025

概括

主要与年龄相关的病 (PART) 是理解大脑衰老和神经退行的一个关键概念. 这次审查考察了 PART 的 PART.

科学领域:

神经病理学神经病理学
神经退行性疾病神经退行性疾病
衰老研究研究衰老研究

背景情况:

主要与年龄相关的病变 (PART) 在2014年被定义为描述没有显著的粉样蛋白的病变.
PART有助于解释生物标志物概况和区分与衰老相关的tau与阿尔茨海默病.
十多年来,PART已经成为了解老年人群早期病的关键.

研究的目的:

为了批判性地评估PART的神经病理特征,临床相关性和分子基础,在PART开始后十年.
综合最近在神经成像,生物标志物,遗传学和流行病学方面的进展,与PART相关.
建议对原始PART标准进行修订,并确定未来的研究重点.

主要方法:

这是一个全面的文献综述,综合了PART研究中的最新发现.
分析神经成像,生物标志物,遗传和流行病学数据.
对现有的神经病理和临床数据进行批判性评估.

主要成果:

PART已被广泛采用,改善了对老化中的病理学的理解.
在神经成像和生物标志物检测方面取得了重大进展,用于PART.
关于PART的致病性,临床意义以及与其他病的关系,仍然存在关键问题.

结论:

PART作为一个有价值的框架,但需要改进其标准.
需要进一步的研究来澄清PART是否是一种独特的疾病,还是普遍的衰老特征.
确定PART的精确机制,生物标志物和临床标准是一个优先事项.

关键词:

衰老的衰老衰老的衰老阿尔茨海默病的神经病理变化 (ADNC)在CA1海马体子场中.认知储备是一种认知储备.康努·阿蒙尼斯2 (CA2) 海马体子场临主导的与年龄相关的TDP-43脑病变神经病理变化 (LATE-NC)主要与年龄相关的病症 (PART)恢复力恢复力

更多相关视频

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells

Published on: October 10, 2017

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Amyloid Fibrils

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...